News
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback